Intermittent versus continuous prostate cancer therapy: New trial raises cautions in metastatic diseaseResearchers unable to conclude the two strategies produce equivalent results Made-in-Canada technology aims to zap early prostate cancerSafety trial of MRI-guided ultrasound ablation launched in Ontario Contrast-free urograms possible in minor hematuria cases Study shows no impact on detection of clinically significant findings Myrbetriq: first beta-3 agonist for overactive bladder coming soon Medication is the first in a new class of drugs used to manage overactive bladder. Patients on androgen-deprivation therapy receive inadequate bone health care Most lack basic information about bone health, are not receiving appropriate screening, and are not engaging in appropriate healthy bone behaviours, study finds. Beware the shrinking penis Researchers raise awareness of a little-known side-effect of prostate cancer therapy From bikes to vibrators: The many ways to hurt the genitals Men suffer most such injuries, but sex toy incidents more common in women What’s best for incontinence? Updated urinary incontinence guidelines Update provides concise approach to the evaluation, management of urinary incontinence in adults. Inlyta for metastatic renal cell carcinoma Drug is the fourth kinase inhibitor to be approved for treatment of metastatic renal cell carcinoma in Canada. First Previous 11 12 13 14 15 Next Last
